MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and
MRI contrast developer Pharmacyclics of Sunnyvale, CA, has signed a contract manufacturing agreementwith Burroughs Wellcome for production of the company's Gadoliteagent. Pharmacyclics is developing Gadolite for enhancement ofMRI scans of the abdomen and pelvis. The agent last month completedphase-three clinical trials and Pharmacyclics plans to submita new drug application in the middle of this year.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.